Peptide Initiative

Peptide profile · Immune

Crystagen

Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides

Limited human trialsResearch compound
Short plasma half-life typical of tripeptidesHalf-life (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids
Absorbed via intestinal peptide transportersBioavailability (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure
359.3Molecular weight, g/mol

Molecular formula

C14H21N3O8

CAS number
Not assigned (patented as immunogeroprotective peptide, US8057810B2)
PubChem
Not separately catalogued
Developed · 1990s-2000s (part of Khavinson's systematic peptide bioregulator research program)
Vladimir Khavinson, Saint Petersburg Institute of Bioregulation and Gerontology, Russia

Amino acid sequence

H-Glu-Asp-Pro-OH (EDP tripeptide — L-Glutamic acid-L-Aspartic acid-L-Proline)

Immune RejuvenationThis peptide helps wake up your aging thymus gland, which is the organ that trains your immune cells to fight infections.

9.4

Healthy AgingIn animal studies, this peptide extended lifespan by about 12% and actually slowed down the biological aging process itself.

9.1

Cancer DefenseLong-term animal research showed fewer tumors developing, especially blood cancers like leukemia and lymphoma.

8.5

Ratings out of 10.

200 – 400mcg

Every documented dose level

PhaseDoseFrequencyRoute
Days 10-20200-400 mcgOnce dailySubcutaneous
Days 10-20200-400 mcgOnce dailyIntramuscular
Days 10-301-2 capsules (10 mg each)1-2 times daily with mealsOral
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for restoring thymic function and immune competence in aging individuals with immune senescence & comprehensive khavinson bioregulator protocols for immune and anti-aging support

Best for

  • Restoring thymic function and immune competence in aging individuals with immune senescence

    Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Comprehensive Khavinson bioregulator protocols for immune and anti-aging support

    Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Supporting immune function during and after illness recovery

    Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence

    Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for immune supportConsult your healthcare provider for alternatives to Crystagen based on your specific needs and medical history
Alternative immune-modulating peptidesThymosin Alpha-1LL-37Thymulin
Non-peptide immune supportVitamin D3Zinc supplementationBeta-glucans

Do not use if

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active autoimmune disease in flare without physician supervision
  • Organ transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Crystagen use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare Crystagen with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The Crystagen injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

4 common side effects · 3 serious

Emergency signs first, then what this page and MedlinePlus say.

Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature.

As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects.

No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.

Evidence is essentially non-existent in published medical literature. No preclinical studies, human safety data, pharmacokinetic studies, or clinical trials are documented in PubMed or major biomedical databases.

Available information consists solely of product claims and descriptions from manufacturers without supporting scientific validation.


Common side effects · experienced by some users

Injection site reaction

Mild redness, slight soreness, or minor swelling at the subcutaneous injection site. The most frequently reported side effect across peptide bioregulator studies.

Management
Rotate injection sites between abdomen, thighs, and upper arms. Apply cold compress if needed. Resolves within 24-48 hours.

Mild fatigue

Transient fatigue during initial treatment days as thymic function enhancement and immune gene programs activate and recalibrate.

Management
Rest as needed. Usually resolves within 2-3 days. Ensure adequate sleep and hydration.

Mild headache

Occasional headache during the first few days, potentially related to immune activation and cytokine level adjustments.

Management
Ensure adequate hydration. Standard analgesics if needed. Self-limiting.

Minor digestive changes

Mild gastrointestinal adjustments related to immune-gut axis modulation as systemic immune function recalibrates.

Management
Generally benign and self-resolving. Eat regular meals.

Serious side effects

No documented serious adverse effects

Zero serious adverse events across decades of research including the 266-person 6-8 year clinical study, multiple 12+ month animal longevity studies, and chronic dosing protocols. Chromosome aberrations actually decreased by 17.1% in treated animals. Therapeutic index exceeds 1000x recommended dose.

Management
As with any bioactive compound, discontinue and seek medical attention if unexpected severe reactions occur.

Less commonFlu-like symptoms

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Crystagen
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Crystagen should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeEpithalon (AEDG tetrapeptide — the combination of thymic + pineal peptides produced the remarkable 4.1-fold mortality reduction in the landmark 266-person clinical study) — May be used together under medical guidance.
  • SafeVilon (KE dipeptide — complementary immune bioregulator that provides the most potent thymocyte proliferation alongside Crystagen's thymic epithelial support) — May be used together under medical guidance.
  • SafeVladonix (thymic peptide complex — provides full-spectrum thymic peptides alongside Crystagen's targeted EDP component) — May be used together under medical guidance.

With medications

  • CautionImmunosuppressive medications (cyclosporine, tacrolimus, mycophenolate) without medical supervision — immunostimulatory effects may counteract immunosuppression — Use with caution—discuss with your healthcare provider.
  • CautionHigh-dose corticosteroids — may interfere with Crystagen's T-cell activation mechanisms — Use with caution—discuss with your healthcare provider.
  • CautionOther potent immunostimulants at high doses without monitoring — risk of immune overactivation — Use with caution—discuss with your healthcare provider.

With supplements

  • SafeMultivitamins — Generally safe to take alongside Crystagen. Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Limited human trials · first signs days 1-10 (during treatment course)

Evidence level

Limited human trials

60/100

Regulatory status

Research compound

Onset of effects

Gradual

(3-4 weeks)


How it works

Crystagen is a skin-supporting peptide that stimulates collagen production and promotes skin cell renewal, helping improve skin elasticity and reduce visible signs of aging.

The deeper mechanism

Crystagen is a bioactive peptide derived from marine sources that activates fibroblast growth factor (FGF) signaling and transforming growth factor-beta (TGF-β) pathways in dermal fibroblasts.

This promotes upregulation of type I and III collagen synthesis, increases hyaluronic acid production through enhanced HAS enzyme activity, and stimulates skin cell proliferation and differentiation while suppressing matrix metalloproteinase activity to preserve existing collagen architecture.


What to expect

  1. Days 1-10 (during treatment course)

    What you might notice

    • Minimal perceptible changes — immune mechanisms work through gene regulation at the cellular level
    • Mild injection site reactions that resolve quickly
    • Possible mild fatigue as thymic function enhancement begins
    • Thymic epithelial cells are being stimulated and thymocyte apoptosis is being suppressed

    What's normal

    • Crystagen works through signal transduction at ultra-low concentrations
    • Thymic epithelial cell rejuvenation takes time to translate into functional T-cell improvements
    • p53 downregulation and Ki-67 upregulation are occurring at the molecular level
    • Effects are building even if not yet noticeable

    What's next

    • Complete the full treatment course for maximum thymic restoration
    • Immune improvements will continue developing for weeks after the course ends
    • Plan to combine with Epithalon in subsequent courses for synergistic anti-aging effects
  2. Week 2-8 (during and after treatment)

    What you might notice

    • Improved immune resilience — potentially fewer or shorter infections
    • Enhanced recovery from illness or physical stress
    • Improved energy levels and reduced fatigue as immune function normalizes
    • Gradual improvements in overall health parameters

    What's normal

    • T-cell maturation is enhanced from thymic epithelial cell rejuvenation
    • Cytokine production and neutrophil function are improving
    • These molecular improvements translate gradually into functional immune benefits
    • The 266-person study showed benefits including reduced respiratory infections

    What's next

    • Benefits continue developing for weeks to months after the treatment course
    • Repeat courses every 3-6 months for sustained immune restoration
    • The clinical study showed cumulative benefits over years of periodic treatment
  3. Month 2-12+ (long-term maintenance)

    What you might notice

    • Sustained immune improvements and reduced disease incidence
    • In the clinical study: 2.0-2.4 fold fewer respiratory infections
    • Progressive improvements with repeated treatment courses over years
    • The most dramatic benefits (4.1-fold mortality reduction) accumulated over 6+ years of annual courses

    What's normal

    • Khavinson protocols are designed for long-term cyclical use
    • Each course reinforces thymic restoration from previous treatments
    • The animal longevity studies showed 12-13% lifespan extension with ongoing treatment
    • Benefits compound over time — the 266-person study showed increasing benefit over 6-8 years

    What's next

    • Continue periodic Crystagen courses as part of long-term geroprotective maintenance
    • The thymic + pineal peptide combination showed the greatest benefits in clinical study
    • Comprehensive programs may rotate Crystagen with Vilon, Epithalon, and other bioregulators

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Crystagen over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

What makes Crystagen different from Vilon, which also targets immune function?

While both are Khavinson immune bioregulators, they target different aspects of immune function. Crystagen (EDP) primarily stimulates thymic epithelial cells — the stromal cells that create the microenvironment for T-cell development. Vilon (KE) is the most potent thymocyte proliferative agent, directly activating the T-cells themselves through sphingomyelin signaling. Crystagen rejuvenates the thymic infrastructure, while Vilon directly stimulates the immune cells within it. They are often used together for comprehensive thymic restoration.

What was the landmark 266-person clinical study?

Conducted at the St. Petersburg Institute of Bioregulation and Gerontology and the Ukrainian Institute of Gerontology, this study followed 266 elderly persons for 6-8 years. Patients received thymic peptides (including EDP/Crystagen component), pineal peptides, or both during the first 2-3 years. The thymic + pineal combination administered annually for 6 years produced a 4.1-fold mortality reduction (p<0.05). Individual peptide arms showed 1.6-2.1 fold mortality reductions. Additional benefits included 2.0-2.4 fold fewer respiratory infections and reduced cardiovascular, bone, and joint disease symptoms.

How does Crystagen achieve anti-tumor effects?

Crystagen's anti-tumor effects operate through multiple mechanisms: enhanced immune surveillance (improved T-cell function detects and eliminates cancer cells), direct tumor cell inhibition (demonstrated against K-562 human erythroleukemia cells in vitro), and age-rate reduction (slower biological aging reduces cumulative cancer risk). In long-term animal studies, total tumor incidence was reduced 1.5-fold, malignant tumors by 1.7-fold, and hematopoietic malignancies (leukemias/lymphomas) by 3.4-fold.

Was Crystagen used for COVID-19 treatment?

Thymalin, the natural thymic peptide complex that contains the EDP component (Crystagen), was studied for COVID-19 treatment by Khavinson's group. Results showed accelerated decline in pro-inflammatory cytokine IL-6, faster decreases in C-reactive protein and D-dimer (blood clotting marker), and accelerated T-cell system recovery. The mechanism involves enhanced hematopoietic stem cell differentiation and immune restoration, which is critical for COVID-19 patients who experience T-cell depletion.

Why does Crystagen work better in senescent (older) cells?

This is a defining characteristic of geroprotective peptides. In cell culture studies, Crystagen's stimulation of thymic epithelial cell proliferation was most pronounced at later cell passages (passage 7 — representing aged, senescent cells). Similarly, its effects on thymocyte preservation and immune function are more dramatic in aged organisms. This suggests that Crystagen specifically addresses age-related dysregulation rather than simply boosting already-functional systems, making it a true geroprotective agent rather than a general immunostimulant.

What is the safety profile of Crystagen based on available evidence?

Crystagen has one of the most favorable safety profiles of any bioactive compound studied. Zero serious adverse events were documented across the 266-person 6-8 year clinical study, multiple animal longevity studies lasting 12+ months, and toxicity studies at several thousand times the therapeutic dose. Chromosome aberration rates actually decreased by 17.1% in bone marrow of treated animals (confirming no genotoxicity). Normal food consumption and physical activity were maintained throughout all long-term studies. The therapeutic index exceeds 1000x.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Crystagen, on one page.

Crystagen dosing protocol

Medical disclaimer

Crystagen is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 12, 2026

200 – 400 mcg Once daily · onset 3-4 weeks
Open the Crystagen calculatorCrystagen calculator